- Home
- NMAI vs LXEO Comparison
NMAI vs LXEO Comparison
Compare NMAI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NMAI | LXEO |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 396.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NMAI | LXEO |
|---|---|---|
| Price | $14.50 | $4.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 87.3K | ★ 876.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $3.99 |
| 52 Week High | $15.06 | $10.99 |
Technical Indicators
Market Signals| Indicator | NMAI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 51.17 |
| Support Level | $13.48 | $4.39 |
| Resistance Level | $15.06 | $5.01 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 54.56 | 35.80 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.